Wolfe Research has recently initiated Bristol-Myers Squibb Co (BMY) stock to Peer Perform rating, as announced on November 15, 2024, according to Finviz. Earlier, on November 13, ...

Research analysts at Zacks Research upped their FY2024 earnings per share estimates for Bristol-Myers Squibb in a research ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report). The company’s shares closed yesterday at $56.80. Don't ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with a ...

Over the weekend, Bristol Myers Squibb & Co (NYSE:BMY) shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), ...

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

On Thursday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $58.5 which represents a slight increase of $0.09 or 0.15% from the prior close of $58.41. The stock opened at ...

Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

Checkpoint Therapeutics' cosibelimab shows strong efficacy in treating cSCC. Learn why CKPT stock could see significant gains ...